Comparison of Sentinel Lymph Node Biopsy by Blue Dye Conjunction With Indocyanine Green or Radioisotope in Early-Stage Breast Cancer: A Prospective Single-Center Observational Study.

Breast cancer indocyanine green methylene blue radioisotope sentinel lymph node biopsy

Journal

Clinical Medicine Insights. Oncology
ISSN: 1179-5549
Titre abrégé: Clin Med Insights Oncol
Pays: United States
ID NLM: 101525771

Informations de publication

Date de publication:
2023
Historique:
received: 22 04 2023
accepted: 28 08 2023
medline: 6 11 2023
pubmed: 6 11 2023
entrez: 6 11 2023
Statut: epublish

Résumé

Although radioisotope (RI) combined with blue dye (BD) is the standard technique for sentinel lymph node (SLN) biopsy in breast cancer, the use of RI is limited at some institutions due to the specific equipment needed. Indocyanine green (ICG) fluorescence detection has been developed as a potential substitute for RI method. However, reports on the sensitivity of ICG and RI techniques in detecting SLN are inconsistent; hence, the present study was designed to compare the clinical efficacy between the combined method of ICG + BD (ICG-B) and RI + BD (RI-B). A prospective observational study was performed that identified 138 breast cancer patients who had undergone lymphatic mapping and SLN biopsy with ICG-B or RI-B. The SLN detection rate, positive SLN counts, and lymph node metastasis between the 2 groups were compared. A total of 71 patients were recruited in the ICG-B group, while 67 were recruited in the RI-B group. The SLN detection rate was 100% in both the ICG-B and RI-B groups. Lymph node metastasis was found in 13 patients using ICG-B and in 12 patients using the RI-B technique (18.31% vs 17.91%, respectively; Indocyanine green combined with BD has an equal efficacy compared with RI plus BD when performing an axillary SLN biopsy in breast cancer. The ICG plus BD procedure is a promising alternative to traditional standard mapping methods.

Sections du résumé

Background UNASSIGNED
Although radioisotope (RI) combined with blue dye (BD) is the standard technique for sentinel lymph node (SLN) biopsy in breast cancer, the use of RI is limited at some institutions due to the specific equipment needed. Indocyanine green (ICG) fluorescence detection has been developed as a potential substitute for RI method. However, reports on the sensitivity of ICG and RI techniques in detecting SLN are inconsistent; hence, the present study was designed to compare the clinical efficacy between the combined method of ICG + BD (ICG-B) and RI + BD (RI-B).
Methods UNASSIGNED
A prospective observational study was performed that identified 138 breast cancer patients who had undergone lymphatic mapping and SLN biopsy with ICG-B or RI-B. The SLN detection rate, positive SLN counts, and lymph node metastasis between the 2 groups were compared.
Results UNASSIGNED
A total of 71 patients were recruited in the ICG-B group, while 67 were recruited in the RI-B group. The SLN detection rate was 100% in both the ICG-B and RI-B groups. Lymph node metastasis was found in 13 patients using ICG-B and in 12 patients using the RI-B technique (18.31% vs 17.91%, respectively;
Conclusions UNASSIGNED
Indocyanine green combined with BD has an equal efficacy compared with RI plus BD when performing an axillary SLN biopsy in breast cancer. The ICG plus BD procedure is a promising alternative to traditional standard mapping methods.

Identifiants

pubmed: 37928452
doi: 10.1177/11795549231201129
pii: 10.1177_11795549231201129
pmc: PMC10624060
doi:

Types de publication

Journal Article

Langues

eng

Pagination

11795549231201129

Informations de copyright

© The Author(s) 2023.

Déclaration de conflit d'intérêts

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Références

Eur Surg Res. 2023;64(2):230-236
pubmed: 36412622
Surg Oncol. 2020 Sep;34:324-335
pubmed: 32791443
BMC Surg. 2023 May 17;23(1):133
pubmed: 37198675
Breast Cancer. 2017 Mar;24(2):341-344
pubmed: 27568304
Eur J Breast Health. 2021 Oct 04;17(4):352-355
pubmed: 34651114
Int J Clin Oncol. 2017 Feb;22(1):11-17
pubmed: 27864624
Ann Surg Oncol. 2021 Jul;28(7):3738-3748
pubmed: 33156466
Asian Pac J Cancer Prev. 2020 May 01;21(5):1187-1195
pubmed: 32458621
Gland Surg. 2021 May;10(5):1677-1686
pubmed: 34164312
Asian J Surg. 2020 Dec;43(12):1149-1153
pubmed: 32143963
J Clin Oncol. 2017 Feb 10;35(5):561-564
pubmed: 27937089
Ann Med Surg (Lond). 2020 Sep 22;59:156-160
pubmed: 33072308
BMC Womens Health. 2018 Sep 18;18(1):151
pubmed: 30227837
Ann Surg Oncol. 2011 Sep;18(9):2483-91
pubmed: 21360250
Biomaterials. 2022 Mar;282:121388
pubmed: 35151934
Breast Cancer. 2005;12(3):211-5
pubmed: 16110291
Nat Commun. 2022 Sep 24;13(1):5613
pubmed: 36153336
JAMA Surg. 2015 Jul;150(7):617-23
pubmed: 26017057
Gland Surg. 2022 Jul;11(7):1139-1147
pubmed: 35935557
J Surg Oncol. 2018 Jun;117(8):1841-1847
pubmed: 29790178
Gland Surg. 2020 Oct;9(5):1495-1501
pubmed: 33224824
JCO Glob Oncol. 2020 Jul;6:1225-1231
pubmed: 32749861
Semin Nucl Med. 2022 Sep;52(5):551-560
pubmed: 35241267
Nanotechnology. 2017 May 5;28(18):185102
pubmed: 28393763
Cancer Biol Med. 2018 Nov;15(4):452-460
pubmed: 30766755

Auteurs

Yanmei Wang (Y)

Department of Breast Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.

Qing Peng (Q)

Department of Breast Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.

Pengcheng Sun (P)

Department of Breast Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.

Xuesha Li (X)

Department of Breast Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.

Yilong Dong (Y)

Department of Physiology, School of Medicine, Yunnan University, Kunming, People's Republic of China.

Classifications MeSH